Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Amortization of Deferred Charges (2019 - 2021)

Historic Amortization of Deferred Charges for Utah Medical Products (UTMD) over the last 3 years, with Q3 2021 value amounting to $11000.0.

  • Utah Medical Products' Amortization of Deferred Charges rose 1000.0% to $11000.0 in Q3 2021 from the same period last year, while for Sep 2021 it was $42000.0, marking a year-over-year increase of 1052.63%. This contributed to the annual value of $39000.0 for FY2020, which is 263.16% up from last year.
  • Per Utah Medical Products' latest filing, its Amortization of Deferred Charges stood at $11000.0 for Q3 2021, which was up 1000.0% from $11000.0 recorded in Q2 2021.
  • In the past 5 years, Utah Medical Products' Amortization of Deferred Charges ranged from a high of $11000.0 in Q2 2021 and a low of $9000.0 during Q2 2019
  • Its 3-year average for Amortization of Deferred Charges is $9909.1, with a median of $10000.0 in 2019.
  • Within the past 5 years, the most significant YoY rise in Utah Medical Products' Amortization of Deferred Charges was 1111.11% (2020), while the steepest drop was 1000.0% (2020).
  • Utah Medical Products' Amortization of Deferred Charges (Quarter) stood at $9000.0 in 2019, then rose by 11.11% to $10000.0 in 2020, then rose by 10.0% to $11000.0 in 2021.
  • Its Amortization of Deferred Charges stands at $11000.0 for Q3 2021, versus $11000.0 for Q2 2021 and $10000.0 for Q1 2021.